HOME >> BIOLOGY >> NEWS
New research holds promise for protecting cancer patients against infertility

Lyon, France: A promising new therapy for protecting the fertility of women with cancer and auto-immune diseases such as lupus was revealed at the 23rd annual conference of the European Society of Human Reproduction and Embryology today (Tuesday 3 July 2007). Dr. Kate Stern, Research Director of the Royal Womens Hospital, Melbourne, Australia, told the conference that her pilot study had shown gonadotropin-releasing hormone (GnRH) antagonists were likely to be able to protect the ovary in women receiving potentially toxic doses of chemotherapy. We are now hoping to carry out a randomised controlled trial to assess the long term protective effect of this treatment, she said

GnRH analogues are commonly used in the management of womens disorders that are dependent on oestrogen production, and in IVF therapies. Dr. Stern and her team studied women between the ages of 18 and 35 years who were due to receive high doses of cyclophosphamide, a chemotherapy drug. They knew that GnHR analogues were already used for the temporary suppression of ovulation in infertility treatment, so reasoned that it would be possible to use it to shut down the ovaries temporarily during the time that chemotherapy was administered, and hence protect them from the effect of the drugs.

The women were given the GnRH antagonist cetrorelix by 3 subcutaneous injections, each of them four days apart, concurrently with their chemotherapy. The scientists observed that there was evidence that ovarian function was suppressed, but that this returned to normal after chemotherapy stopped. Follicle stimulating hormone levels were up in 73% of the patients, but these also subsequently returned to normal. 94% of the patients resumed spontaneous ovulation and menses within 12 months.

We believe that using GnRH antagonists in this way could reduce the side effects of chemotherapy over a long period, said Dr. Stern. Other studies have tried to analyse whether sim
'"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
3-Jul-2007


Page: 1 2

Related biology news :

1. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
2. Saudi Arabias KAUST names WHOI first research partner
3. Multinational research: protecting ecology means understanding people, too
4. Newly created cancer stem cells could aid breast cancer research
5. Carnegie Mellons Peter Adams receives EPA research grant
6. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
7. Innovative tagging technique may help researchers better protect fish stocks
8. Penn researchers discover how key protein stops inflammation
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. ASU researchers partner with UOP to make biofuel for military jets a reality
11. Einstein researchers prototype vaccine could provide improved protection against tuberculosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: